AZD0424 is an Orally Active and Dual Selective Src/Abl Kinase Inhibitor
A study from Victoria K Woodcock suggested that AZD0424 is an inhibitor of the proto-oncogenic non-receptor tyrosine kinases Src and ABL1. The kinase plays an indefensible role in cancer. Src expresses lowly in the majority of cell types and participates in regulating bone metabolism, proliferation, and angiogenesis. Src also...
CHMFL-ABL-039, a Selective Type II Native and Drug-Resistant Mutant BCR-ABL Inhibitor for Chronic Myeloid Leukemia
Chronic myeloid leukemia (CML) is a white blood cell disorder, accounting for about 15% of adult leukemias. The critical driving force of pathogenesis of CML identified is BCR gene and ABL kinase gene fusion. It results in the constitutive activation of ABL kinase. And the activation is essential for...